Two-year translational funding (USD 250,000) to accelerate druggable pathways and deliver cancer interception/prevention strategies for RUNX1-FPD—aimed at stopping clonal hematopoiesis from progressing to MDS/AML and moving findings toward the clinic.
Eligibility Criteria:
-
MD/PhD (or equivalent) at a non-profit institution (U.S. or international; citizenship not required).
-
Demonstrated expertise in hematopoiesis and/or immunology; proposals must clearly target prevention/interception in RUNX1-FPD.
-
Other active grants allowed with documented plans to avoid scientific/budget overlap; collaboration encouraged.
Funding Details:
-
USD 250,000 total over 2 years (≤ USD 125,000/year); direct costs only; no indirects; NIH salary cap applies.
-
Allowable: personnel, fringe, supplies, small equipment, reasonable travel; one no-cost extension possible.
-
Resource/Data Sharing plan required.
Deadline:
-
Full proposal due December 11, 2025 (8:00 p.m. ET).
-
Notification: February 2026.
-
Projected term: April 2026 – April 2028.
Where to Go for Further Information:
-
Apply via ProposalCentral (ALSF — RARE Grant).
-
Program contacts: Dr. Katrin Ericson — [email protected]; ALSF grants — [email protected].